Company: SRPT
Filing Date: 2025-03-03
Form Type: S-3ASR
Source: 0001193125-25-044088
Chunk: 25

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-03-03
Form: S-3ASR
Chunk 25
---
 from another report that we file with the Commission, the form of each warrant agreement relating to warrants offered under this prospectus. 17

The particular terms of any issue of warrants will be described in the prospectus supplement relating to the issue. Those terms may include:

| • |     | the number of shares of common stock or preferred stock purchasable upon the exercise of warrants to purchase 
 such shares and the price at which such number of shares may be purchased upon such exercise;                 |

| • |     | the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion and      
 voting rights) of the series of preferred stock purchasable upon exercise of warrants to purchase preferred stock; |

| • |     | the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise 
 price for the warrants, which may be payable in cash, securities or other property;                            |

| • |     | the date on which the right to exercise the warrants will commence and the date on which the right will expire; |

| • |     | United States federal income tax consequences applicable to the warrants; and |

| • |     | any additional terms of the warrants, including terms, procedures, and limitations relating to the exchange, 
 exercise and settlement of the warrants.                                                                     |

Holders of equity warrants will not be entitled:

| • |     | to vote, consent or receive dividends; |

| • |     | receive notice as shareholders with respect to any meeting of shareholders for the election of our directors or 
 any other matter; or                                                                                            |

| • |     | exercise any rights as shareholders of Sarepta Therapeutics, Inc. |

Each warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of preferred stock or common stock at the exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. A holder of warrant certificates may exchange them for new warrant certificates of different denominations, present them for registration of transfer and exercise them at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any warrants to purchase debt securities are exercised